Sygnature Discovery Acquires NuChem Sciences

NuChem Sciences Acquires IniXium

October 31, 2022

Biotechnology

Montreal-based contract research organization NuChem Sciences has acquired IniXium of Laval, Québec, with investment support from the Fonds de solidarité FTQ. The deal expands NuChem's structural biology and recombinant protein production capabilities—integrating IniXium's crystallography and fragment screening expertise into NuChem's drug-discovery services.

X-Chem Acquires IntelliSyn and AviSyn to Expand Drug Discovery Services

January 26, 2021

Biotechnology

X-Chem, a portfolio company of GHO Capital, has acquired Montreal-based IntelliSyn and its US-based sister company AviSyn to extend its drug discovery offering into medicinal chemistry, custom synthesis and scale-up process chemistry. The deal integrates downstream hit validation and lead optimisation capabilities into X-Chem’s DNA-Encoded Library (DEL) platform, enabling a streamlined screen-to-lead service for pharma and biotech clients; financial terms were not disclosed.

Certara Acquires Chemaxon to Expand Drug Discovery Software Capabilities

July 9, 2024

Software

Certara, Inc. has signed a definitive agreement to acquire Chemaxon, a leading cheminformatics software provider, with the transaction expected to close in the second half of 2024, subject to regulatory approvals. The acquisition adds Chemaxon’s discovery-focused cheminformatics tools to Certara’s biosimulation portfolio, enabling a more comprehensive data and predictive-analytics platform spanning discovery through development.

Novo Holdings Acquires Altasciences from Audax Private Equity

February 22, 2021

Healthcare Services

Novo Holdings has agreed to acquire Altasciences, a Laval, Canada–headquartered contract research and CDMO services provider, from Audax Private Equity. Altasciences— which operates six facilities across the U.S. and Canada and employs over 1,300 people—will remain led by CEO Chris Perkin and is expected to continue expanding domestically and internationally under Novo Holdings' ownership.

eMolecules Acquires Synple Chem AG

September 24, 2024

Biotechnology

eMolecules, a San Diego-based provider of a chemical compound search-and-fulfillment platform and a portfolio company of Avista Healthcare Partners, has acquired Synple Chem AG, an automated chemical synthesis systems and services provider headquartered near Zurich, Switzerland. The acquisition adds Synple's automation technology and a virtual compound library of more than 7 trillion tractable compounds to eMolecules' existing offering, expanding its capabilities as a one-stop shop for compound procurement, management and automation for drug discovery customers.

ANI Pharmaceuticals Acquires Novitium Pharma for $163.5M

March 9, 2021

Pharmaceuticals

ANI Pharmaceuticals completed the acquisition of Novitium Pharma for $163.5 million (including $89.5M cash and $74M equity, plus up to $46.5M in contingent earn-outs), adding a U.S.-based R&D engine and CDMO manufacturing capacity. The deal, financed with a new $300M Term Loan B, a $40M revolver and a $25M PIPE investment from Ampersand Capital Partners, is expected to be immediately accretive and expand ANI's generics, contract manufacturing and 505(b)(2) capabilities.